Holen Sie sich die Stockscreener-App
22.03
5.41%
1.13
Vorhandelsmarkt:
21.86
-0.17
-0.77%
Schlusskurs vom Vortag:
$20.90
Offen:
$21.24
24-Stunden-Volumen:
178.18K
Relative Volume:
1.08
Marktkapitalisierung:
$341.24M
Einnahmen:
$925.00K
Nettoeinkommen (Verlust:
$-90.35M
KGV:
-5.1994
EPS:
-4.237
Netto-Cashflow:
$-78.10M
1W Leistung:
+12.97%
1M Leistung:
+9.66%
6M Leistung:
+26.57%
1J Leistung:
+55.14%
1-Tages-Spanne:
$20.81
$23.35
1-Wochen-Bereich:
$18.23
$23.35
52-Wochen-Spanne:
$6.875
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
22.03 | 341.24M | 925.00K | -90.35M | -78.10M | -4.237 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Craig Hallum | Buy |
| 2025-05-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Neurogene (NASDAQ:NGNE) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Neurogene: Q4 Earnings Snapshot - theheraldreview.com
Neurogene Inc. Advances Gene Therapy for Rare Neurological Diseases with EXACT Platform and NGN-401 Clinical Development - Minichart
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway - TipRanks
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Neurogene 10-K: Revenue $0.0M, EPS $(4.24) on $90.4M net loss - TradingView
Neurogene (NASDAQ: NGNE) details Rett gene therapy progress and cash runway - Stock Titan
Neurogene Reports Positive Interim Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome and Advances Toward Commercialization in 2026 - Minichart
William Blair reiterates Neurogene stock rating on trial progress - Investing.com
William Blair reiterates Neurogene stock rating on trial progress By Investing.com - Investing.com Australia
Leerink reiterates Neurogene stock rating on Rett syndrome progress By Investing.com - Investing.com Australia
Neurogene Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Neurogene : Corporate Presentation March 2026 - marketscreener.com
NGN-401 clinical developments and financials drive Neurogene Inc. corporate update - Traders Union
NGNE: NGN-401 advances with full trial enrollment, FDA Breakthrough status, and strong cash runway - TradingView
Neurogene (NGNE) deepens Rett gene therapy push with 2025 loss and long cash runway - Stock Titan
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates - marketscreener.com
BRIEF-Neurogene FY Operating Expenses USD 103.328 Million - TradingView
Rett syndrome gene therapy clears 50% dosing, no HLH cases yet - Stock Titan
Neurogene Inc.: Fundamental Analysis and Financial Ratings | | US64135M1053 - marketscreener.com
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference - MarketBeat
Neurogene Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
Neurogene Inc: chief scientific officer Cobb sells $141k in stock - Investing.com
Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 4,045 Shares of Stock - MarketBeat
Neurogene (NASDAQ:NGNE) Insider Sells 6,797 Shares - MarketBeat
Neurogene (NGNE) CSO sells 6,797 shares under 10b5-1 plan - Stock Titan
Tax-driven share sale by Neurogene (NGNE) president and CFO disclosed - Stock Titan
Published on: 2026-03-17 03:31:12 - baoquankhu1.vn
Neurogene (NGNE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
[144] Neurogene Inc. SEC Filing - Stock Titan
Latest NGNE NewsNeurogene Announces NGN-401 Gene Therapy fo... - Stock Titan
Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Bluefield Daily Telegraph
Genetic-medicine firm Neurogene in Stifel 2026 virtual CNS fireside chat - Stock Titan
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
NGNE: Durable functional gains in Rett syndrome drive NGN-401's pivotal trial and commercial plans - TradingView
NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, with pivotal data expected mid-2024 - TradingView
Gains Recap: Whats the analyst consensus on Neurogene Inc2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Will Neurogene Inc. stock outperform value stocksInsider Buying & Accurate Buy Signal Alerts - Naître et grandir
Aug Update: How correlated is Neurogene Inc to the S P500Chart Signals & Community Consensus Trade Alerts - baoquankhu1.vn
Layoff Watch: Is Neurogene Inc part of any major indexJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Aug Movers: Is Neurogene Inc backed by strong institutional buyingJuly 2025 Breakouts & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Macro Review: Is Neurogene Inc in a long term uptrend2025 Market WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Neurogene Inc. (NGNE) CFO sells 4,800 shares under 10b5-1 plan - Stock Titan
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
NGNE SEC FilingsNeurogene 10-K, 10-Q, 8-K Forms - Stock Titan
Should You Buy Neurogene Inc (NGNE) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Neurogene: Stock Soars On FDA Designation For Rett Gene TherapyI'd Remain Cautious - Seeking Alpha
Canaccord Genuity Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - Nasdaq
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurogene Inc-Aktie (NGNE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO |
Mar 13 '26 |
Sale |
20.81 |
4,045 |
84,176 |
105,798 |
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):